News in brief: Shire's Canadian merger delayed

UK company Shire Pharmaceuticals has said that its proposed $3.5bn (€3.9bn) merger with Canadian firm BioChem will be delayed.

A review period for the merger ends on March 31, but the Canadian minister of industry said that he would not be able to reach a conclusion by that time. Merrill Lynch is financial adviser to BioChem as well as being joint broker to Shire. Deutsche Bank and Bear Stearns are advising Shire.

WSJ Logo
Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a BillionaireExternal link

Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a Billionaire